ALK and lung carcinoma: A recent study by Zhuang et al. 33 involving a cohort of 3774 Chinese NSCLC patients reported a lower co-mutation rate of 1.67% in 5 tested driver genes (EGFR, KRAS, ALK, ROS1 and BRAF) while 5% of patients in another cohort of 1,000 NSCLC patients at The NCI’s Lung Cancer Mutation Consortium were reported to harbour concomitant driver gene mutations48.